AFMD News and Press, Affimed N.V. From 06/30/22

Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and oncology Scientific Advisory Board to provide guidance on the Company’s development strategy across assets and assessment of emerg...

Affimed has generated an impressive pipeline of innate cell engagers programs created using their three-pronged development strategy. These programs target high unmet needs and large market opportunities. Affimed recently finalized a $103.5M public offering, which will help fund the c...

AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-nega...

Affimed N.V. (AFMD) Q1 2022 Results Conference Call June 01, 2022 08:30 AM ET Company Participants Alex Fudukidis - Head of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Arndt Schottelius - Chief Scientific Officer Wolfgang Fischer - Chief Op...

Affimed press release (NASDAQ:AFMD): Q1 GAAP EPS of -€0.14. Revenue of €8.02M (-31.2% Y/Y). Based on the company’s current operating plan and assumptions, cash and cash equivalents, including proceeds from the April 2022 public offering, are expected to support opera...

AFM13 monotherapy: Completed enrollment in the REDIRECT study for patients with relapsed or refractory PTCL; on track to report topline data in the fourth quarter of 2022 AFM13 combination with NK cells: Reported data at AACR 2022 showing a 100% objective response rate (ORR) and ...

Affimed (NASDAQ:AFMD) is scheduled to announce Q1 earnings results on Wednesday, June 1st, before market open. The consensus EPS Estimate is -$0.20 (-1900.0% Y/Y) and the consensus Revenue Estimate is $9.66M (-17.2% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and ...

Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy in patients with advanced EGFR-expressing solid tumors Design and rationale of the phase 1/2a study of AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid t...

HEIDELBERG, Germany, May 26, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Execut...

HEIDELBERG, Germany, May 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release ...